The Board has decided to defer the declaration of an interim dividend. While the Company continues to maintain a healthy financial position and robust liquidity, the Board intends to preserve capital as of now to provide necessary flexibility to the Company to evaluate other potential strategic avenues / corporate actions which can maximize long-term shareholder value. The Board may evaluate this at an appropriate time and the decision, if any, thereon shall be intimated by the Company to the Stock Exchange(s).
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Advanced Enzyme Technologies Limited held its Board meeting on May 09, 2026 and approved the audited consolidated financial results for FY 2025-26. The company reported consolidated revenue from operations of Rs 7,457.57 million, up 17% from Rs 6,369.10 million in the previous year. Profit after tax grew significantly by 29.6% to Rs 1,736.08 million from Rs 1,339.74 million. While recommending a final dividend of Rs 1.35 per share (67.5%) for shareholder approval at the AGM, the Board decided to defer the declaration of an interim dividend. The company stated it wants to preserve capital to evaluate potential strategic avenues and corporate actions that could maximize long-term shareholder value. The auditors issued an unmodified (clean) opinion on the financial statements.
The deferral of interim dividend suggests the company is holding cash for potential M&A or strategic investments. However, the strong PAT growth of ~30% and clean audit opinion indicate healthy financials, which should be positive for long-term investors.